Novo Nordisk (NVO) said Tuesday it has filed for European Medicines Agency approval of a new, higher dose of its obesity treatment Wegovy, or semaglutide.

The application is supported by clinical trial data showing that treatment with the higher 7.2 mg subcutaneous dose led to an average 21% reduction in body weight among people with obesity with or without type 2 diabetes, with one in three patients achieving 25% or more weight loss, Novo Nordisk said.

The higher dose had a safety profile consistent with the currently approved 2.4 mg dose, the company added.

Price: 69.36, Change: +0.04, Percent Change: +0.06